Physician profile
Kenya E Thomas
NPI 1588285480
$1,924.87
in general payments reported to CMS, 2019-2025
16 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $110 · 2024: $590 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,815.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $498.57 | 2022-2025 | Biktarvy |
| Abbvie INC. | $450.00 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $186.82 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $153.70 | 2022-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $147.71 | 2024-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $131.61 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.85 | 2024-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $61.76 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $39.56 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $30.17 | 2024 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $27.40 | 2024-2025 | |
| Seqirus USA INC | $21.28 | 2025 | Fluad, Flucelvax |
| Edwards Lifesciences Corporation | $21.19 | 2024 | Sapien 3 Ultra Resilia |
| Astellas Pharma US INC | $19.29 | 2024 | Veozah |
| Shield Therapeutics INC | $16.22 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $13.74 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenya Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.